2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 12, 2019

9:00AM-11:00AM: Abstract Number: 2389

Treat to Target by Specific Cytokine Interdiction: Multiple Biomarker Disease Activity Test Deconstructed

RA – Treatments Poster III: Safety and Outcomes

9:00AM-11:00AM: Abstract Number: 2337

Treat to Target Is Not Linked to Best Myocardial Strain Indices: Is There Really a Myocardial Dysfunction Directly Associated with Disease Activity?

RA – Diagnosis, Manifestations, & Outcomes Poster III: Comorbidities

9:00AM-11:00AM: Abstract Number: 2383

Treatment for Rheumatoid Arthritis After Methotrexate-associated Lymphoproliferative Disorder Developed

RA – Treatments Poster III: Safety and Outcomes

9:00AM-11:00AM: Abstract Number: 2340

Treatment of Interstitial Lung Disease and Airway Disease Complicated with Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster III: Comorbidities

9:00AM-11:00AM: Abstract Number: 2520

Treatment of SLE Patients with the Immunoproteasome Inhibitor KZR-616: Results from the First 3 Cohorts of an Open-Label Phase 1b Dose Escalation Trial

SLE – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2369

Treatment Patterns with Disease Modifying Anti-rheumatic Drugs in United States Veterans with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis

RA – Treatments Poster III: Safety and Outcomes

9:00AM-11:00AM: Abstract Number: 2691

Treatment Patterns, Disease Burden and Outcomes in Patients with Giant Cell Arteritis and Polymyalgia Rheumatica

Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2266

Treatment Preferences in Patients with Axial Spondyloarthritis

Patient Outcomes, Preferences, & Attitudes Poster II: Patient Preferences, Beliefs, & Experiences – ARP

9:00AM-11:00AM: Abstract Number: 2343

Treatment with Biologic DMARDs Does Not Increase Risk of Severe Pulmonary Events in Patients with Rheumatoid Arthritis and Pre-existing Lung Disease

RA – Diagnosis, Manifestations, & Outcomes Poster III: Comorbidities

9:00AM-11:00AM: Abstract Number: 2202

Trends in Prescribing of NSAIDs and Opioids Among Osteoarthritis Patients in British Columbia, Canada, 1998-2014

Osteoarthritis – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 1934

Tripartite Motif (TRIM) Gene Family Expression in Dermatomyositis

Genetics, Genomics & Proteomics Poster

9:00AM-11:00AM: Abstract Number: 2097

Tuberculin Skin Test and Quantiferon®-TB Gold In-Tube Test for Latent Tuberculosis Before Biologic Treatments: Lower Agreement Rate in Spondyloarthropathies Compared to Rheumatoid Arthritis

Infection-Related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 1933

Tumorigenesis Related Gene Identification in Dermatomyositis Using Meta-Analysis

Genetics, Genomics & Proteomics Poster

9:00AM-11:00AM: Abstract Number: 1944

Two Biomarkers with Predictive Capacity to Diagnosis Pre-Radiographic Knee Osteoarthritis: Data from the Osteoarthritis Initiative

Genetics, Genomics & Proteomics Poster

9:00AM-11:00AM: Abstract Number: 2373

Two Decades of Changes in RA Treatment and Disease Outcomes from the United States

RA – Treatments Poster III: Safety and Outcomes

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].